• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Harris

Articles by Michael Harris

Life Isn’t as Sweet as it May Seem in Biotech’s C-Suites

Sep. 18, 2012
By Michael Harris
Biotechnology is an idiosyncratic industry in which some executives can stake their careers on the pursuit of orphan drugs that, at best, will offer only limited opportunity for corporate profits and investors returns, while addressing the usually unmet needs of a narrow patient base. Other biotech execs pin their aspirations to the old-school home-run approach of developing a blockbuster drug to address a prevalent indication such as diabetes, and then basking for the next decade in the blockbuster revenue it generates. Either way, success in biotech is a conceded longshot. And success is usually considered to be more of a...
Read More

Russia Emerging from Behind Iron Curtain with Innovation

Aug. 23, 2012
By Michael Harris
A string of first-ever events for Russia, including its official admittance to the World Trade Organization, plus committed government support to build a biopharma industry means the nation once known as the Kremlin may be in need of a more modern nickname as it transforms from an emerging market to one that could compete alongside the U.S., Japan and Europe.
Read More

Russia Ready to Build a 'Permanent' Biopharma Market

Aug. 9, 2012
By Michael Harris
Emerging market nations may be the all the rage in biopharma, and there are many countries that aspire to achieve that strategic level, but the Russian Federation wants to be more than just another BRIC in the wall.
Read More

Is it Better to Forgive and Pharm-merge?

Aug. 6, 2012
By Michael Harris
Aug. 5 was International Forgiveness Day, and the founding organization of this annual effort, Worldwide Forgiveness Alliance (WFA), says in its mission statement that a goal is to promote and publicize the research findings that show forgiveness creates better health, abundance, greater optimism and lessens depression, stress, illness and disease. It also deems forgiveness as the greatest healer of all, able to impart more lasting, happy, supportive relationships. Well, that statement’s certainly applicable in biopharma – particularly in M&A transactions, inasmuch as the pardon-begets-profit model can be observed whenever a hostile takeover finally closes and the executive of a formerly...
Read More

The Pharm-eleon is Shedding its Pharma-saurus Skin Again

July 30, 2012
By Michael Harris
If the big pharmas are indeed dinosaurs, they have learned to do what their predecessors could not: survive! Pharma may be prehistoric in terms of age compared to biotech, but it maneuvers more like a velociraptor than lumbering brontosaurus, as it commonly consumes everything in its path that can impend, contest or abet its dominance. Likely, 100 years from now, pharma will still be standing and bio-who? will be so assimilated into the DNA of pharma that its individuality is what will be extinct. Increasingly, pharma is obliging all of us to disregard the biotech industry as a standalone entity...
Read More

The IPO problem keeps tick, tick, ticking for small med-techs

July 16, 2012
By Michael Harris

IPO Problem Keeps Tick, Tick, Ticking for Small Firms

July 16, 2012
By Michael Harris
NEW YORK – Regulators are endeavoring to take steps to boost the prospects for small companies to partake in the initial public offering (IPO) market, but more can be done to help not only companies going public today, but those that went public in the pre-healthcare reform era and that have been burdened and are struggling with the side effects of overregulation for years, according to someone the SEC actually listens to.
Read More

Intellectual Property Is Safe Behind the BRIC Wall

July 6, 2012
By Michael Harris
In the U.S., it costs about $15,000 to $20,000 and can take up to three years to process a biotech patent application. The time frame for the process in the BRIC (Brazil, Russia, India, China) nations is comparable to that, but the costs are generally a lot less, and those nations also are taking resolute measures to dispel any apprehension, as well as any external challenges – such as theft-by-illegal-generics and corruption – that foreign-based drugmakers may perceive, or fear, to be an issue.
Read More

BIO-Buzzwords Won’t Die, So We May as Well Evolve Them

June 25, 2012
By Michael Harris
For BIO 2011, BioWorld published a list of overused BioCliches to shun, and I was pleased to observe that attendees and speakers must’ve taken notice and avoided using them at BIO 2012 this year. However, since the urge to use buzzwords will never die, we should at least regenerate the list every now and then before the catchwords become so stale they wind up in the dictionary and your parents are using them. Since we made a weekend beeline from BIO 2012 to return to all corners of the globe, I offer some new words to kick off the bio-summer...
Read More

BRIC Markets Have Stopped Emerging; They've Arrived

June 22, 2012
By Michael Harris
BOSTON – Is it practical to still designate China – a market that is closing in on Japan as the world's second-largest pharma market – as a potential market? Or regard Russia's biopharma industry status as an emerging one, when its clinical trials infrastructure is rated in the global top five by the FDA?
Read More
Previous 1 2 3 4 5 6 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe